New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil

https://doi.org/10.1016/j.meegid.2021.104998Get rights and content

Highlights

  • A Sanger-based method to genotype SARS-CoV-2 and to address the prevalence of variants of concern (VOC) has been developed.

  • The distribution of SARS-CoV-2 lineages overtime shows that VOC P.1 is now predominant in Rio de Janeiro.

  • SARS-CoV-2 VOC are able to infect vaccinees, irrespective of the vaccine immunogen or number of doses taken.

Abstract

After a one-year rollout of the pandemic caused by SARS-CoV-2, the continuous dissemination of the virus has generated a number of variants with increased transmissibility and infectivity, called variants of concern (VOC), which now predominate worldwide. Concerns about the susceptibility of humans that have already been infected before or those already vaccinated to infection by VOC rise among scientists and clinicians. Herein, we assessed the prevalence of different VOC among recent infections at the Brazilian National Cancer Institute (Rio de Janeiro, Brazil). By using a Sanger-based sequencing approach targeting the viral S gene to identify VOC, we have analyzed 72 recent infections. The overall prevalence of VOC was 97%. Among the subjects analyzed, six had been vaccinated with the ChAdOx1-S/nCoV-19 (n = 4; one with two doses and three with one dose) or the CoronaVac (n = 2; both with 2 doses) vaccine, while five subjects represented reinfection cases, being two of them also part of the vaccinated group (each one with one vaccine type). All vaccinated and re-infected subjects carried VOC irrespective of the vaccine type taken, the number of doses taken, IgG titers or being previously infected during the first wave of the Brazilian pandemic. Importantly, all six vaccinees only had mild symptoms. We present here several examples of how natural infections or vaccination may not be fully capable of conferring sterilizing immunity against VOC

Keywords

SARS-CoV-2
Reinfection
VOC
Vaccine
Immune escape

Cited by (0)

1

These authors contributed equally to this work.

View Abstract